Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Hemoglobin S (HbS) polymerization is the central molecular event underlying sickle cell disease (SCD). It occurs when deoxygenated HbS molecules aggregate to form long, rigid fibers within red blood cells. This process distorts the shape of erythrocytes, leading to their characteristic "sickled" appearance and resulting in impaired blood flow, hemolysis, and a range of acute and chronic complications. The polymerization is triggered by a single point mutation in the β-globin gene (β6 Glu→Val) and is influenced by factors such as oxygen tension, hemoglobin concentration, and the presence of other hemoglobins like fetal hemoglobin (HbF). Preventing or reversing HbS polymerization is a major therapeutic strategy.
Allosteric modulation of hemoglobin oxygen affinity to prevent deoxygenation-induced polymerization
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Hemoglobin S Polymerization (HbS Polymerization).